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INTRODUCTION
Since the introduction of nucleoside analogues in the 1960s, further progress has made this class of drugs into one of the most active component of therapy for patients with hematopoietic malignancies. [1] [2] [3] [4] Although several analogues such as fludarabine, cladribine, nelarabine, gemcitabine, and deoxycoformycin have been introduced to the clinic, cytarabine (ara-C) remains the only active nucleoside analogue for treatment of adult acute myeloid leukemia (AML). 5, 6 Clofarabine (2-chloro-2'-fluoro-deoxy-9--D-arabinofuranosyladenine) was synthesized as a hybrid molecule to overcome the limitations of fludarabine and cladribine and to incorporate their best qualities. 7 Halogenation at the 2-position of adenine and substitution of a fluorine group at the C-2' position of the arabinofuranosyl moiety were essential for many of the characteristic features of clofarabine: i) high resistance to phosphorolytic cleavage by bacterial purine nucleoside phosporylase; ii) increased acid stability stimulating the development of an oral compound; iii) resistance to deamination by adenosine deaminase; and iv) the DNA-directed activity of clofarabine. [8] [9] [10] [11] Because of its similarity to fludarabine and cladribine, it was postulated that clofarabine would be active in indolent leukemias rather than the adult acute leukemias. In both phase I and phase II investigations of clofarabine as a single agent, impressive clinical activity without neurotoxicity was observed in patients with acute leukemias, especially AML.
Among the 32 heavily pretreated patients in the phase I study of clofarabine, 5 patients responded to this therapy. The maximum tolerated dose (MTD) on a 5-day schedule was 40 mg/m 2 /day for patients with acute leukemias with hepatotoxicity as the dose-limiting toxicity
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From clofarabine on days 2 through 5, as previous studies demonstrated that this was the time of maximum clofarabine triphosphate accumulation in leukemia blasts. 13 On the first day, ara-C was infused alone to characterize the ara-CTP pharmacokinetics in leukemia blasts for comparison with that on day 2, when ara-C was given after the first clofarabine infusion. with incomplete platelet recovery (CRp), or partial response (PR) was achieved. Patients who did not achieve at least a PR after 2 induction courses were taken off study. Responding patients could receive up to 6 additional cycles of maintenance therapy at 75% of the induction doses of both clofarabine and ara-C. Dose level reductions were implemented for grade 2 extramedullary toxicities (25%) and grade 3 extramedullary toxicities including life-threatening infections (50%).
Consolidation therapy and dose reductions due to toxicities could be modified at the discretion of the treating physician as judged to be in the best interests of the patient. pharmacologic, and metabolic evaluation were collected at specified time points on days 1 through 6 during cycle 1. Supportive measures for optimal medical care were provided throughout the study as determined by the treating physician and the patient's medical need. Hematopoietic growth factors were allowed in patients with serious neutropenic complications ( grade 3 febrile neutropenia or obvious sepsis). 23 All patients gave written informed consent for plasma and cellular pharmacology investigations.
Plasma Pharmacokinetics
Samples were obtained prior to therapy on day 1 for baseline values, prior to clofarabine infusion on day 2, at the end of the 1-hour infusion, and at 2, 3, 4, 5, 6, and 24 hr after the start of therapy.
Additional samples (prior to end of infusion, and 6 hr) were obtained on days 3 to 5. On the 6 th day when clofarabine was infused as a single agent, samples were taken as on day 1 to compare the influence of ara-C infusion on clofarabine pharmacokinetics. The plasma was removed after centrifugation and stored at -70 o C until analyses were performed. Human plasma samples (100 µL) containing clofarabine were spiked with cladribine as the internal standard. Samples were precipitated, evaporated, and reconstituted with mobile phase. The samples were analyzed by reversed-phase high performance liquid chromatography coupled to a tandem quadrupole mass spectrometer by a modified previously described procedure by MicroConstants, Inc. (San Diego, CA). 24 Authentic clofarabine standard was used for assay validation, and for identification and quantitation of the nucleoside in plasma. The assay has a sensitivity range from 10 to 5000 ng/mL. The CV for precision was less than 7% and the accuracy was within +/-7%.
Pharmacokinetic data were analyzed using compartmental models with nominal blood draw times as the independent variable. A 2-compartment model was fit to each individual patient's pharmacokinetic data using the Nelder-Mead algorithm with inverse predicted concentration used as the weights. All analyses were conducted using WinNonlin Professional, version 4.0 (Pharsight Corp., Mountain View, CA).
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Cellular Pharmacology
For cellular pharmacology, samples were obtained on days 1 and 2. Samples were taken prior to therapy, at the end of clofarabine infusion, and 1, 2 or 3 hr after start of ara-C infusion. Cell pellets from blood samples were diluted with phosphate-buffered saline, and mononuclear cells were isolated using Ficoll-Hypaque density-gradient step-gradient centrifugation procedures described previously. 25 A Coulter electronics channelizer (Coulter Corporation, Hialeah, FL) was used to determine the mean cell volume. After being washed with phosphate-buffered saline, cells were processed for nucleotide extraction. Normal nucleotides, ara-CTP, and clofarabine triphosphate were extracted from cells using standard procedures with HClO 4 . Triphosphates were separated on an anion-exchange Partisil-10 SAX column (Waters Corporation, Milford, MA)
using HPLC as described in detail previously. 25 The intracellular concentration was calculated and expressed as the quantity of nucleotides contained in the extract from a given number of cells of a determined mean volume. This calculation assumes that nucleotides are uniformly distributed in total cell water. In general, the lower limit of quantitation of this assay was approximately 1 pmol in an extract of 2 x 10 7 cells, corresponding to a cellular concentration of approximately 0.2 MM.
Statistical Analyses
This was an open-label, phase I-II dose-escalation study with no randomization. The primary objective of phase I of the study was to determine the MTD and DLT of clofarabine when used in combination with ara-C. The dose escalation used the 3+3 design. 12 All grade 3 drug-related toxicities were considered DLTs with the exception of nausea and vomiting (if manageable with supportive care measures), alopecia, drug-related fever, and lymphopenia. Secondary objectives were to evaluate the efficacy of this treatment regimen and to study the biochemical modulation of ara-CTP when given in combination with clofarabine. This is a single-arm study with objective tumor response as the primary efficacy end point of the phase II portion of the trial. Efficacy
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RESULTS

Study Population
A total of 32 patients were treated. Their characteristics are summarized in Table 1 . Twelve patients (3 per each dose cohort) were enrolled in the phase I part of the study, whereas the remaining 20 patients participated in the phase II part. The median age of the whole study population was 59 years (range, 18 to 84 years). There were 25 patients with AML, 4 with highrisk MDS as defined by 10% blood or marrow blasts, 1 with CML in myeloid blast phase (resistant to imatinib), and 2 patients with ALL. With the exception of the CML patient who received the clofarabine/ara-C combination as frontline therapy for blast phase, all other patients were either primary refractory (n=7) to the preceding induction regimen, or received the study treatment as first salvage following relapse (n=24). Among the patients with AML and MDS, 16 had experienced a first remission duration of less than 12 months, and 6 patients were in remission for at least 12 months or longer. Cytogenetic analysis revealed abnormal karyotypes in 11 patients with AML.
Response and Outcome
Response rates are shown in Table 2 . Among all patients, 7 (22%) achieved CR, and 5 (16%) CRp, for an overall response rate of 38%. No responses occurred in 3 patients with ALL and CML. Among the 29 patients with AML/MDS, 7 patients (24%) achieved CR. Another 5 patients (17%) had hematologic improvement (CRp) for an overall response rate of 41% in this group. In with a median overall survival of responding patients of 7.9 months (1.7-8.3+).
Side Effects
Common side effects of the clofarabine/ara-C combinations included nausea/vomiting, diarrhea, skin rashes including hand-foot syndrome, and mucositis (Table 4) . During the phase I portion of the study, no dose-limiting toxicities (DLT) were observed during each of the 2-week observation periods necessary to establish further dose escalation. Facial flushing and headaches were noted during chemotherapy administration and typically resolved upon completion of the infusion. The side effect profile of the phase I and phase II populations was similar, although a higher incidence of hand-foot-syndrome (palmoplantar erythrodysesthesia) was observed during phase 2 at the higher doses of clofarabine (40 mg/m 2 /day). Transient liver dysfunctions were common. In the phase I portion, grade 2 hyperbilirubinemia was observed in 8 patients (67%) and elevations of transaminases in 5 patients (42%). These occurred anywhere between days 7 to 28 of cycle 1, but were most commonly clustered around days 7 to 11. Likewise, hyperbilirubinemia was seen in 16 patients (80%) of the phase II part and elevations of transaminases in 13 (65%). Only 2 patients (10%) experienced grade 3 hyperbilirubinemia.
In the combined phase I and II studies, myelosuppression-associated complications included at least one febrile episode in 20 of 32 patients (63%) ( Table 5 ). Fever of unknown origin occurred in 10 patients (31%). Documented infections included 20 episodes of bacterial infections (predominantly catheter-related infections due to coagulase-negative staphylococcus) and 3 episodes of fungal infections (at least one fungal pneumonia). One early death occurred at day 11 due to myelosuppression-associated complications (bacterial sepsis) and was not considered study drug-related.
Plasma Pharmacokinetics
Each subject's pharmacokinetic results are presented in Table 6 . A 2-compartment model appeared to adequately characterize the plasma pharmacokinetics of clofarabine. No systematic trend in the residuals was observed over time for any patient. The residuals also appeared to be Figure 1 presents the median concentrationtime profiles for each dose group and the model predicted concentrations. Concentrations increased with increasing dose. No evidence of nonlinearity was observed in the data, although the number of subjects at each dose level was too small to detect nonlinear pharmacokinetics.
To determine if clofarabine plasma pharmacology was affected by ara-C infusion, clofarabine levels on day 2 were compared with those on day 6. On day 1 ara-C was infused alone; on day 2 ara-C was infused 4 hours after clofarabine administration. On day 6, clofarabine was infused alone ( Table 7 ). The levels of clofarabine at the end of a 1-hour infusion were similar on day 2 and 6 (p = 0.694). Also, the plasma concentration of clofarabine at 6 hours after start of infusion were similar in patients on day 2 and day 6 (p = 0.12), suggesting that ara-C infusion did not significantly affect the clofarabine plasma levels.
Cellular Pharmacokinetics
The objective of the cellular pharmacokinetics investigations was to determine if clofarabine triphosphate accumulation increases ara-CTP accumulation in circulating leukemia cells. Limited pharmacokinetics investigations were done in 8 patients due to relatively low number of circulating leukemia cells in this patient population (Table 8) . Our previous studies suggested that a 20% variation in ara-CTP concentration is expected. 18, 19 Hence values below 0.8 or above
1.2 were considered significant for a decline or increase in ara-CTP value when intracellular concentrations of ara-CTP were compared on day 1 versus day 2. With this cutoff point, 5 of 8 patients had an increase in ara-CTP accumulation after clofarabine infusion.
DISCUSSION
In this phase I-II study we combined clofarabine, a novel nucleoside analogue with antileukemic activity, with ara-C for patients with relapsed and refractory acute leukemias, high-risk MDS, and blast phase CML. This study represents an important extension of the previous single-agent 
29-34
Single-agent clofarabine is active in acute leukemias. The phase I adult study included 32 patients with acute leukemias, 5 of whom (16%) responded (2 CR and 3 CRp). 12, 35 Higher responses were demonstrated in a phase I pediatric study. Of 22 evaluable children, 8 (36%) had an objective response including 5 children (23%) who achieved CR according to the investigator. 36 The adult phase I study defined a clofarabine dose of 40 mg/m 2 daily for 5 days per course as the dose for phase 2 studies, the DLT being hepatotoxicity. A phase II study of singleagent clofarabine in patients with refractory and relapsed acute leukemias has recently been completed. 13 Significant antileukemic activity was observed in AML, MDS, and CML blast phase.
Of 62 patients, 30 (48%) achieved a response (CR, CRp, or PR). In AML and high-risk MDS, the response rates were 42% and 25%, respectively. Response rates in AML were as high as 87% in patients with long first remission durations (>12 months) or and 67% for those treated with clofarabine as second or subsequent salvage therapy.
In consideration of mechanistic rationales for use of clofarabine with other agents, it is clear that clofarabine exhibits many of the characteristics of fludarabine that would contribute to increasing the metabolism of ara-C in leukemia blasts. The rate-limiting step in the synthesis of ara-CTP is
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From catalyzed by dCyd kinase. The activity of dCyd kinase in turn is regulated by intracellular level of dNTPs. Clofarabine, like fludarabine, is a potent inhibitor of RnR and therefore able to decrease levels of dNTP. 10, 11 This leads to a decrease in the feedback inhibition of dCyd kinase thus allowing increased production and accumulation of ara-CTP. That there can, indeed, be biochemical synergy between ara-CTP and clofarabine has been demonstrated in K562 cells in vitro. 26 In this model system, 3-hr pretreatment with clofarabine followed by incubation with ara-C, led to a 2-fold increase in the concentration of ara-CTP relative to cells incubated with ara-C alone. Such biochemical modulation strategies for increasing intracellular nucleotide analogue concentrations has been demonstrated clinically in combination strategies of ara-C with either fludarabine or cladribine in adult acute leukemias 18, 19 ,29-34,37, 38 and in pediatric acute leukemias.
39, 40
In the present study of patients with relapsed and refractory AML and MDS, we report a CR rate of 24% and an overall response rate (including patients with CRp) of 41%. Only 1 patient died during induction (within 4 weeks of therapy start) constituting an induction mortality of 3%. The CR rate of 24% in AML and high-risk MDS compares favorably with that of standard therapy in this poor-prognosis group, but is lower than the 42% CR rate in relapsed AML reported in the single-agent clofarabine phase 2 study. 13 This may be due to two factors. First, the combination study included a dose-finding phase I portion in which 9 patients received doses of clofarabine below the single-agent MTD dose of 40 mg/m 2 /day x 5 days. Second, patient selection may have played a role. Whereas in the combination study 28% patients with AML had primary refractory disease to initial induction, and an additional 44% had a first remission duration of less than 12 months, only 35% of the AML population in the single-agent phase II study had a first remission duration of less than 12 months or had primary refractory disease.
The combination regimen was well tolerated, and both agents could be given at full doses. With single-agent intermittent infusion of ara-C, the DLTs were neurotoxicity and pulmonary toxicity. 41 Neurotoxicity, especially central nervous system-associated adverse effects, has been the major For personal use only. on August 30, 2017. by guest www.bloodjournal.org From problem with high-dose ara-C. 42 In contrast, the single-agent clofarabine DLT was hepatic in nature. 12, 13 The non-overlapping toxicity profiles of these 2 agents allowed us to administer the full dose of each in this combination regimen, without untoward effects. The major toxicities of the combination regimen were gastrointestinal including transient liver test abnormalities, nausea/vomiting, diarrhea, and mucositis. Although skin rashes were frequently observed, they rarely exceeded grade 2 by NCI toxicity criteria. CNS toxicity was not observed. This was in contrast to the fludarabine and ara-C combination treatment, where 8 of 219 (3.7%) patients suffered from neurotoxicity. 43 This positive attribute of the clofarabine and ara-C regimen indicates that this combination may be suitable for elderly AML patients.
Because of the sampling design it was not possible to statistically determine whether coadministration with ara-C resulted in a pharmacokinetic drug interaction. In a previous study in 13 adults with refractory or relapsed AML dosed once daily for 5 days with 40 mg/m 2 clofarabine by 1-hr intravenous infusion, the observed clearance, volume of distribution at steady-state, andhalf-life was estimated at 30.6 L/hr, 294 L, and 6.2 hr, respectively (unpublished data). The plasma pharmacokinetic parameters observed in this study were consistent with those in patients with refractory or relapsed AML dosed with clofarabine single-agent, suggesting that no gross pharmacokinetic interaction was occurring between ara-C and clofarabine.
Cellular pharmacology of ara-CTP and clofarabine triphosphate suggested that clofarabine triphosphate accumulation resulted in an increase in ara-CTP accumulation in the leukemia blasts, validating the biochemical modulation strategy. However, the increase in ara-CTP accumulation was observed in only 5 of 8 patients, suggesting that there is heterogeneity among patients regarding augmentation of ara-CTP. This could be due to low intracellular levels of clofarabine triphosphate; indeed circulating leukemia blasts of patients 1 and 9, whose blasts had undetectable level of clofarabine triphosphate, did not increase ara-CTP accumulation on day 2.
On the other hand, blasts from patient 17 had a 1.5-fold increase in ara-CTP even with 4 µM clofarabine triphosphate. Because the sampling time is only once daily and the data are limited
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From to 8 patients, the biochemical modulation effect of clofarabine needs to be fully investigated and then compared with that previously reported for fludarabine or cladribine. With the limited experience of clofarabine and ara-C to date, it appears that clofarabine does not result in higher levels of intracellular ara-CTP accumulation than has previously been reported with fludarabine.
In summary, clofarabine is one of the few nucleoside analogues (besides ara-C) that has shown activity in adult AML as a single agent and at well-tolerated doses. Clofarabine triphosphate is accumulated and retained in leukemia blasts, resulting in a decline of leukemia cells, and making it an ideal candidate for biochemical modulation strategies. We have shown that clofarabine can be safely combined with ara-C, and that the combination has clinical activity. Evaluation of this combination strategy in older patients with newly diagnosed AML and high-risk MDS is currently ongoing. Further mechanism-based combinations of clofarabine with other active agents (anthracyclines, alkylators) are planned.
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